

INSTEP Trial

ACTRN12605000082606

Status	RECRUITING
Phase	Phase 3
Sponsor	Gavin M Wright
Enrollment	100 participants

Plain Language Summary

This study, called the INSTEP Trial, looks at whether taking a pain relief medication called Celebrex (celecoxib) after a surgical procedure to treat a collapsed or recurrent lung (pleurodesis via VATS) affects how well the lung sticks to the chest wall. This sticking is important for the procedure to be successful. The study will compare patients who take Celebrex to those who take a placebo (dummy pill).

You may be eligible if:

- You are 18 years of age or older
- You are having a surgical procedure (pleurodesis) for a recurrent or persistent collapsed lung (pneumothorax)

You may NOT be eligible if:

- You regularly take NSAID pain medications (like ibuprofen) and cannot stop them for more than 24 hours before surgery
- You have kidney problems (renal impairment)

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (1)

- Patients with surgical indication for pleurodesis due to recurrent or persistent pneumothorax

Exclusion (2)

- Chronic NSAID usage that cannot be stopped for more than 24 hours prior to surgery.
- Renal impairment

Locations (1 total)

St Vincent's Hospital (Melbourne) Ltd - Fitzroy, VIC, Australia